Patel Chintu 4

What Happened
Chintu Patel, Co‑CEO and director of Amneal Pharmaceuticals (AMRX), received two equity awards on March 2, 2026: 190,632 restricted stock units (RSUs) and 354,031 performance‑based RSUs. The grants are reported as derivative awards (acquired at $0.00 in the Form 4) — the 190,632 are time‑based RSUs and the 354,031 are performance RSUs (the filing reports the maximum number issuable).

Key Details

• Transaction date: March 2, 2026; Form 4 filed March 3, 2026 (timely).
• Reported grant amounts: 190,632 time‑based RSUs and 354,031 performance RSUs; both shown at $0.00 acquisition price (derivative awards).
• Shares owned after transaction: Not specified in the provided filing.
• Vesting: Time‑based RSUs vest in four equal annual installments beginning March 2, 2027. Performance RSUs vest (if earned) in full on February 28, 2029.
• Performance payout: Performance RSUs pay out based on average closing‑price targets at the end of the three‑year performance period; payout may range from 0% to 200% of the target award. The 354,031 figure represents the maximum possible shares issuable.
• Footnotes: Each RSU equals one contingent right to receive one Class A common share upon vesting.

Context
These are grants of restricted stock units — no shares were delivered immediately. Time‑based RSUs signal expected future compensation and align management with shareholders over the vesting period; performance RSUs are contingent on stock price targets and can yield anywhere from 0% to 200% of target shares. Awards are common executive compensation and do not represent an open‑market purchase or sale.